Raifarm operates in the high-growth, emerging markers of Russia, the CIS, Eastern Europe, and China. These countries have a combined population of approximately two billion people and are characterized by enormous growth potential. Russia, for example, has averaged a 7% annual economic growth from 2002 to 2007, becoming a Top-10 global economy in size. Despite ongoing economic turmoil, emerging markets are expected to quickly recover and return to strong growth.

Pharmaceutical markets have been likewise robust, as both the government and general public started to consider healthcare and health a top priority and substantially increased their pharmaceutical spending. In 2008, despite the global financial crisis, the Russian pharmaceutical market grew by 27% to $14 billion – a remarkable development. Expensive foreign drugs have disproportionately been beneficiaries of this movement. Large foreign pharmaceutical companies have seen their sales grow as much as 100% in recent years. Clearly, it is a great time to enter these emerging markets.